modelFaropenem
Extends from Pharmacolibrary.Drugs.ATC.J.J01DI03.
Information
| name: | Faropenem | |
| ATC code: | J01DI03 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 13.7 | L |
| clearance: | 10.4 | L/h |
| other parameters in model implementation | ||
Faropenem is an orally administered beta-lactam antibiotic belonging to the penem class, structurally related to carbapenems. It is primarily used to treat various bacterial infections, including respiratory tract, urinary tract, and skin infections. While not approved in the United States, it is available and used clinically in countries such as Japan and India.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.
References
Schurek, KN, et al., & Zhanel, GG (2007). Faropenem: review of a new oral penem. Expert review of anti-infective therapy 5(2) 185–198. DOI:10.1586/14787210.5.2.185 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17402834
Yamada, T, et al., & Ukimura, A (2022). Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations. Diagnostic microbiology and infectious disease 103(1) 115662–None. DOI:10.1016/j.diagmicrobio.2022.115662 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35321800
Srivastava, S, et al., & Gumbo, T (2016). Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 63(suppl 3) S102–S109. DOI:10.1093/cid/ciw483 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27742641
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)